Corheart 6 LVAS Long-term Follow-up Study

Inclusion Criteria: * 1\. Age ≥ 18 years. * 2\. The patient or legal representative is willing to participate in the study and offers informed consent. * 3\. Body surface area (BSA) ≥ 1.0 m\^2. * 4\. Females of childbearing age must agree to use adequate contraception. * 5\. Patients with NYHA Class IV heart failure symptoms who have failed to be reversed by standardized treatment with oral anti-heart failure drugs. * 6\. Left Ventricular Ejection Fraction (LVEF) ≤ 35%, and at least one of the following conditions occurs: * a. Fail to be reversed by or be weaned from intra-aortic balloon pump (IABP), extracorporeal membrane oxygenator (ECMO), or other short-term mechanical circulatory support. * b. Rely on continuous intravenous administration of one or more vasoactive or inotropic drugs. * c. Meeting the diagnostic criteria of cardiogenic shock: blood pressure \< 90/60mmHg, cardiac index \< 2.0 L/min/m\^2 (optional), and pulmonary capillary wedge pressure \> 18mmHg (optional). Exclusion Criteria: * 1\. Etiology of heart failure due to or associated with uncorrected thyroid disease, obstructive hypertrophic cardiomyopathy, or pericardial disease. * 2\. Presence of an active, uncontrolled infection confirmed by a combination of clinical symptoms and laboratory tests. * 3\. Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator. * 4\. Intolerance to anticoagulant or antiplatelet therapies or any other peri/postoperative therapy the investigator will require based on the patient's health status. * 5\. Patients require bi-ventricular assist device support. * 6\. Pregnancy. * 7\. Presence of moderate to severe aortic insufficiency or a history of the mechanical aortic valve that will not be converted to a bioprosthesis or oversewn at the time of implantation. * 8\. History of any organ transplantation. * 9\. Presence of uncorrected thrombocytopenia or severe coagulopathy, such as diffuse intravascular coagulation. * 10\. TBIL (total bilirubin) \> 3.0 mg/dL within 48 hours prior to implantation. * 11\. Serum creatinine (SCr) \> 3.0 mg/dL within 48 hours prior to implantation or may require dialysis. * 12\. Presence of severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease or a diagnosis of primary pulmonary hypertension. * 13\. Presence of pulmonary embolism within 3 weeks prior to implantation. * 14\. Pulmonary artery systolic pressure exceeds 60mmHg, combined with at least one of the following 2 parameters demonstrating that pulmonary vascular resistance did not respond to drug therapy: * a. Pulmonary vascular resistance greater than 8 wood units. * b. The transpulmonary differential pressure exceeds 20mmHg. * 15\. Established and untreated abdominal or thoracic aortic aneurysm \> 5cm in diameter. * 16\. Presence of severe peripheral vascular disease with resting pain or extremity ulceration. * 17\. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management, or brain death from various causes. * 18\. History of documented disabling stroke within 90 days prior to implantation, a history of cerebrovascular disease, or the presence of uncorrected severe bilateral carotid artery stenosis. * 19\. History of acute myocardial infarction within 60 days prior to implantation, judged by the investigator to have a risk of myocardial rupture or other surgical high-risk difficult-to-control bleeding, etc. * 20\. Expected lifetime of less than 1 year due to malignant tumor or other disease. * 21\. Participation in any other clinical study that may influence the results of this study. * 22\. Other circumstances that are unforeseen and determined by the researcher to be unsuitable.